PAM抑制剂在HR+和HER2-晚期乳腺癌中的研究进展  

Advances of PAM inhibitors in HR+and HER2-advanced breast cancer

作　　者：朱晓兰 常晓飞 侯雪冬 董文文 史建军 崔猛胜 ZHU Xiaolan;CHANG Xiaofei;HOU Xuedong;DONG Wenwen;SHI Jianjun;CUI Mengsheng(Department of Postgraduate Studies,Changzhi Medical College/Department of Breast Surgery,Heping Hospital Affiliated to Changzhi Medical College,Changzhi 046000,China)

机构地区：[1]长治医学院研究生处,长治医学院附属和平医院乳腺外科,山西长治046000

出　　处：《中国肿瘤外科杂志》2024年第1期93-99,共7页Chinese Journal of Surgical Oncology

基　　金：山西省长治医学院附属和平医院2020年度院级科研基金(HPYJ202017)。

摘　　要：PI3K/AKT/mTOR信号通路抑制剂(PAM信号通路)是一种新型的靶向药物,其作用机制在于阻断PAM信号通路的上游和下游分子,使其在肿瘤中的传递受阻,从而达到抑制肿瘤细胞增殖的目的。目前,内分泌治疗是激素受体阳性(HR+)和人表皮生长因子受体2阴性(HER2-)晚期乳腺癌最主要的治疗方式,但是随着治疗的持续推进,其有效性受到新发或获得性耐药的限制。随着多项临床试验研究结果的出现,PAM通路抑制剂在无进展生存期(PFS)方面显示出了明显的优势并成为逆转内分泌耐药的有效药物。因此,该文详细阐述了PAM抑制剂在HR+和HER2-乳腺癌中的作用机制,重点强调3种PAM抑制剂在HR+和HER2-晚期乳腺癌临床试验中的有效性及安全性。此外,该文还对PAM抑制剂在HR+和HER2-晚期乳腺癌治疗中的临床应用前景进行总结,以期为今后的临床研究提供参考。PI3K/AKT/mTOR signaling pathway inhibitor(PAM signaling pathway)is a novel type of targeted medication that inhibits tumor cell growth by blocking the upstream and downstream components of the PAM signaling pathway.Endocrine therapy for Hormone-positive breast cancer(HR+)and human epidermal growth factor receptor 2 negative(HER2-)is currently the predominant treatment for advanced breast cancer;nevertheless,as treatment advances,its effectiveness is restricted by new or acquired resistance.PAM pathway inhibitors have demonstrated clear advantages in progression-free survival(PFS)in various clinical trials and have become effective medications for reversing endocrine resistance.As a result,this paper elaborates on the mechanism of action of PAM inhibitors in HR+and HER2-advanced breast cancer clinical trials,with a focus on the efficacy and safety of three PAM inhibitors.This report also described the clinical application possibilities of PAM inhibitors in the treatment of HR+and HER2-advanced breast cancer,in order to give references for future clinical studies.

关 键 词：PI3K抑制剂 AKT抑制剂 MTOR抑制剂 乳腺癌 临床研究 

分 类 号：R737.9[医药卫生—肿瘤]